Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Buildings: 2015-2019

Historic Buildings for Myriad Genetics (MYGN) over the last 5 years, with Sep 2019 value amounting to $18.2 million.

  • Myriad Genetics' Buildings fell 3.70% to $18.2 million in Q3 2019 from the same period last year, while for Sep 2019 it was $18.2 million, marking a year-over-year decrease of 3.70%. This contributed to the annual value of $18.8 million for FY2019, which is 2.59% down from last year.
  • As of Q3 2019, Myriad Genetics' Buildings stood at $18.2 million, which was down 3.19% from $18.8 million recorded in Q2 2019.
  • In the past 5 years, Myriad Genetics' Buildings ranged from a high of $20.5 million in Q1 2018 and a low of $16.1 million during Q4 2016.
  • Over the past 3 years, Myriad Genetics' median Buildings value was $18.7 million (recorded in 2019), while the average stood at $18.5 million.
  • Per our database at Business Quant, Myriad Genetics' Buildings declined by 13.30% in 2017 and then climbed by 25.77% in 2018.
  • Quarterly analysis of 5 years shows Myriad Genetics' Buildings stood at $17.3 million in 2015, then fell by 6.94% to $16.1 million in 2016, then rose by 22.98% to $19.8 million in 2017, then increased by 8.00% to $18.9 million in 2018, then dropped by 3.70% to $18.2 million in 2019.
  • Its Buildings stands at $18.2 million for Q3 2019, versus $18.8 million for Q2 2019 and $18.6 million for Q1 2019.